A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Galactoglucomannan-rich hemicellulose extract from Norway spruce (Picea abies) exerts beneficial effects on chronic prostatic inflammation and lower urinary tract symptoms in vivo
Tekijät: Konkol Y, Vuorikoski H, Tuomela J, Holmbom B, Bernoulli J
Kustantaja: ELSEVIER SCIENCE BV
Julkaisuvuosi: 2017
Journal: International Journal of Biological Macromolecules
Tietokannassa oleva lehden nimi: INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Lehden akronyymi: INT J BIOL MACROMOL
Vuosikerta: 101
Aloitussivu: 222
Lopetussivu: 229
Sivujen määrä: 8
ISSN: 0141-8130
eISSN: 1879-0003
DOI: https://doi.org/10.1016/j.ijbiomac.2017.03.079
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/25299888
Galactoglucomannan (GGM) is the main hemicellulose class in wood of coniferous trees and could be potentially utilized as a possible health-promoting substance for food and pharmaceutical industry. Our aim was to evaluate effects of orally administered GGM-rich extract from Norway spruce in a rat model of chronic prostatitis associated with lower urinary tract symptoms (LUTS). Prostatic inflammation and LUTS was induced in male rats using testosterone and 17 beta-estradiol exposure for 18 weeks. Rats were treated with 2% GGM dissolved in drinking water during weeks 13-18. Pelvic pain response, LUT function and histopathological evaluation of the prostate were assessed. The results show that hormonal exposure induced LUTS seen as decreased urine flow rate, increased bladder pressure, voiding times, bladder capacity and residual urine volumes. GGM had positive effects on urodynamical parameters by decreasing the basal bladder pressure, increasing the urine flow rate and volume, reducing the residual volume and increasing micturition intervals. GGM reduced the extent of the hormone exposure-induced prostatic inflammation. Increase of pelvic pain induced by hormone exposure was only slightly affected by GGM treatment. The results suggest that orally administered GGM may have potential usage for improving lower urinary tract function associated with chronic prostatic inflammation. (C) 2017 Elsevier B.V. All rights reserved.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
